William Doyle - Novocure Executive Chairman
| NVCR Stock | USD 29.85 9.81 48.95% |
Chairman
Mr. William F. Doyle is Executive Chairman of the Board of the Novocure Ltd. Mr. Doyle has served as a director of Optinose, Inc., a commercialstage specialty pharmaceuticals company, since 2004 and Minerva Neurosciences, Inc., a clinicalstage biopharmaceutical company, since 2017. Mr. Doyle has also been the managing director of WFD Ventures LLC, a private VC firm he cofounded, since 2002 and was formerly a member of the investment team at Pershing Square Capital Management L.P., a private investment firm. Prior to 2002, Mr. Doyle was a member of Johnson Johnsons Medical Devices and Diagnostics Group Operating Committee and was vice president, Licensing and Acquisitions. While at Johnson Johnson, Mr. Doyle was also chairman of the Medical Devices Research and Development Council, Worldwide president of BiosenseWebster, Inc. and a member of the board of directors of Cordis Corporation and Johnson Johnson Development Corporationrationration, Johnson Johnsons VC subsidiary. Mr. Doyle holds an S.B. in materials science and engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. Mr. Doyle serves on Harvard Business Schools Board of Deans Advisors and MITs Institute of Medical Engineering Science Visiting Committee since 2016.
| Age | 62 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | No. 4 The Forum, Saint Helier, Jersey, JE2 4UF |
| Phone | 44 15 3475 6700 |
| Web | https://www.novocure.com |
William Doyle Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Doyle against Novocure stock is an integral part of due diligence when investing in Novocure. William Doyle insider activity provides valuable insight into whether Novocure is net buyers or sellers over its current business cycle. Note, Novocure insiders must abide by specific rules, including filing SEC forms every time they buy or sell Novocure'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Doyle over six months ago Acquisition by William Doyle of 40000 shares of Minerva Neurosciences at 2.9 subject to Rule 16b-3 |
Novocure Management Efficiency
The company has return on total asset (ROA) of (0.0793) % which means that it has lost $0.0793 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3971) %, meaning that it created substantial loss on money invested by shareholders. Novocure's management efficiency ratios could be used to measure how well Novocure manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/03/2024, Return On Tangible Assets is likely to drop to -0.19. In addition to that, Return On Capital Employed is likely to drop to -0.25. At this time, Novocure's Non Current Assets Total are relatively stable compared to the past year. As of 12/03/2024, Non Currrent Assets Other is likely to grow to about 14.7 M, while Net Tangible Assets are likely to drop slightly above 267.8 M.Similar Executives
| Found 10 records | CHAIRMAN Age | ||
| Curt Hartman | CONMED | 60 | |
| Steven Barker | Masimo | 79 | |
| Marilyn Nelson | Inspire Medical Systems | 81 | |
| Adam JD | Penumbra | 62 | |
| Adam Elsesser | Penumbra | 62 | |
| Bill Sanford | Integer Holdings Corp | 76 | |
| William Kozy | LivaNova PLC | 72 | |
| Joseph Kiani | Masimo | 59 | |
| Mark Tryniski | CONMED | 60 | |
| David Paul | Globus Medical | 57 | |
Management Performance
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.0793 |
Novocure Leadership Team
Elected by the shareholders, the Novocure's board of directors comprises two types of representatives: Novocure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novocure. The board's role is to monitor Novocure's management team and ensure that shareholders' interests are well served. Novocure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novocure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Burke, Chief Officer | ||
| Frank Leonard, Executive Oncology | ||
| Asaf Danziger, CEO and Director | ||
| Uri MD, Chief Officer | ||
| Piet MD, Head VP | ||
| Pritesh Shah, Chief Commercial Officer | ||
| Ashley Cordova, Chief Officer | ||
| Moshe Giladi, Chief Officer | ||
| Wilhelmus Groenhuysen, Chief Officer | ||
| Pr MD, Founder CTO | ||
| MBA MD, Chief Officer | ||
| Ingrid Goldberg, VP Relations | ||
| Barak Arye, General Counsel | ||
| Mukund Paravasthu, Chief Officer | ||
| William Doyle, Executive Chairman | ||
| Michael Puri, Chief Officer |
Novocure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novocure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.0793 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 2.95 B | ||||
| Shares Outstanding | 108.2 M | ||||
| Shares Owned By Insiders | 9.25 % | ||||
| Shares Owned By Institutions | 86.67 % | ||||
| Number Of Shares Shorted | 5.67 M | ||||
| Price To Earning | 721.15 X |
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.